Tracks arm swelling in breast cancer patients on targeted therapy
Follows breast cancer patients on targeted therapy to measure arm swelling using devices.
Plain-language title generated from the registry record
Registry title: Screening For BCRL In Targeted Therapy For Breast Cancer
Key facts
- Where
- Boston, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT05142800, who can take part
Where in United States
- Massachusetts General HospitalBoston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Massachusetts General Hospital
- Trial code
- NCT05142800
- Record updated
- 10 November 2026
- Original description
This a prospective, longitudinal study designed to track edema and Breast Cancer Related Lymphedema (BCRL) onset in breast cancer patients taking targeted therapy treatments for early and metastatic breast cancer.Read full original descriptionShow less
Screening for Edema and Breast Cancer-Related Lymphedema in Patients Undergoing Targeted Therapy for Breast Cancer
This a prospective, longitudinal study designed to track edema and Breast Cancer Related Lymphedema (BCRL) onset in breast cancer patients taking targeted therapy treatments for early and metastatic breast cancer.
A Perometer and Sozo devise will be used to measure volume changes
Inclusion: Subjects who are receiving treatment in the MGH Breast Cancer Center who are enrolled in a DF/HCC-regulated targeted therapy trial for the treatment of early or metastatic breast cancer or patients being treated with a targeted therapy that may alter their risk of developing edema or BCRL will be eligible; Subjects that will be eligible for the study include:; Females between 18 and 80 years of age; With a history of breast cancer; 4 weeks or more post-surgery; With or without edema; Undergoing treatment with targeted therapy for early or metastatic disease.
Exclusion: Patients who cannot attain 90 degrees of shoulder abduction (position of measurement with Perometer).